Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Dec 9, 2010 (rev. 1)

Premium

WaferGen Biosystems this week named Timothy Triche to its scientific advisory board.

Triche is a professor of pathology and pediatrics at the University of Southern California Keck School of Medicine and director of the Center for Personalized Medicine at Children's Hospital Los Angeles. Until recently, Triche was chief of pathology and laboratory medicine at CHLA for more than 20 years. Prior to that, Triche was section chief and head of molecular diagnostics in the laboratory of pathology at the National Cancer Institute.


Bernd Brust will move from his current position as president of Life Technologies' commercial operations and into the role of president of molecular medicine, Life Tech disclosed in a filing last week with the US Securities and Exchange Commission.

Brust will be replaced as president of commercial operations at the beginning of the coming year by Nicolas Barthelemy, who has been leading the firm's Cell Systems division.

Life Technologies said that the Molecular Medicine business unit was formed to enable it to develop new strategies related to transitioning next-generation sequencing activities into clinical uses.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.